Format

Send to

Choose Destination
Clin Cancer Res. 2009 Oct 1;15(19):5945-6. doi: 10.1158/1078-0432.CCR-09-1650. Epub 2009 Sep 29.

Inhibiting the hypoxia response for cancer therapy: the new kid on the block.

Author information

1
Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, Texas, USA.

Abstract

The hypoxia-inducible transcription factor (HIF)-1alpha inhibitor KC7F2 described in this issue of Clinical Cancer Research is the newest addition to an emerging class of antitumor agents targeting the hypoxia response. Here, we discuss the proposed mechanism of action of KC7F2 and its potential strengths and limitations in comparison with other promising HIF-1alpha inhibitors.

PMID:
19789327
PMCID:
PMC2760048
DOI:
10.1158/1078-0432.CCR-09-1650
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center